Matches in SemOpenAlex for { <https://semopenalex.org/work/W2519021239> ?p ?o ?g. }
- W2519021239 endingPage "354" @default.
- W2519021239 startingPage "348" @default.
- W2519021239 abstract "Monoagent DNA-alkylating chemotherapies like dacarbazine are among a paucity of medical treatments for advanced carcinoid tumors, but are limited by host toxicity and intrinsic chemoresistance through the base excision repair (BER) pathway via poly (ADP-ribose) polymerase (PARP). Hence, inhibitors of PARP may potentiate DNA-damaging agents by blocking BER and DNA restoration. We show that the PARP inhibitor ABT-888 (Veliparib) enhances the cytotoxic effects of dacarbazine in carcinoids. Two human carcinoid cell lines (BON and H727) treated with a combination of ABT-888 and dacarbazine resulted in synergistic growth inhibition signified by combination indices <1 on the Chou-Talalay scale. ABT-888 administered prior to varying dacarbazine doses promoted the suppression of neuroendocrine biomarkers of malignancy, ASCL1 and chromogranin A, as shown by western analysis. Ataxia telangiectasia mitogen factor phosphorylation and p21Waf1/Cip1 activation, indicative of DNA damage, were increased by ABT-888 when combined with dacarbazine treatment, suggesting BER pathway attenuation by ABT-888. PE Annexin V/7-AAD staining and sorting revealed a profound induction of apoptosis following combination treatment, which was further confirmed by increased PARP cleavage. These results demonstrate that ABT-888 synergizes dacarbazine treatment in carcinoids. Therefore, ABT-888 may help treat carcinoids unresponsive or refractory to mainstay therapies." @default.
- W2519021239 created "2016-09-23" @default.
- W2519021239 creator A5027616097 @default.
- W2519021239 creator A5060329995 @default.
- W2519021239 creator A5073811035 @default.
- W2519021239 creator A5075308122 @default.
- W2519021239 creator A5082762194 @default.
- W2519021239 date "2016-09-16" @default.
- W2519021239 modified "2023-10-06" @default.
- W2519021239 title "The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids" @default.
- W2519021239 cites W1540983225 @default.
- W2519021239 cites W1674116136 @default.
- W2519021239 cites W1882891727 @default.
- W2519021239 cites W1912887175 @default.
- W2519021239 cites W1917632054 @default.
- W2519021239 cites W1927461076 @default.
- W2519021239 cites W1940434397 @default.
- W2519021239 cites W1966682923 @default.
- W2519021239 cites W1967880683 @default.
- W2519021239 cites W1977447340 @default.
- W2519021239 cites W1990509102 @default.
- W2519021239 cites W1991192536 @default.
- W2519021239 cites W1997486111 @default.
- W2519021239 cites W2001902450 @default.
- W2519021239 cites W2008997722 @default.
- W2519021239 cites W2011350308 @default.
- W2519021239 cites W2011916383 @default.
- W2519021239 cites W2016444964 @default.
- W2519021239 cites W2019775979 @default.
- W2519021239 cites W2022811243 @default.
- W2519021239 cites W2034058449 @default.
- W2519021239 cites W2035386385 @default.
- W2519021239 cites W2035566238 @default.
- W2519021239 cites W2037352738 @default.
- W2519021239 cites W2038869171 @default.
- W2519021239 cites W2044949198 @default.
- W2519021239 cites W2045900545 @default.
- W2519021239 cites W2047082284 @default.
- W2519021239 cites W2049921243 @default.
- W2519021239 cites W2062618966 @default.
- W2519021239 cites W2072261547 @default.
- W2519021239 cites W2077945404 @default.
- W2519021239 cites W2086824644 @default.
- W2519021239 cites W2090232354 @default.
- W2519021239 cites W2091206206 @default.
- W2519021239 cites W2093988174 @default.
- W2519021239 cites W2096287682 @default.
- W2519021239 cites W2107276199 @default.
- W2519021239 cites W2110046124 @default.
- W2519021239 cites W2118672029 @default.
- W2519021239 cites W2118682535 @default.
- W2519021239 cites W2127104690 @default.
- W2519021239 cites W2128879260 @default.
- W2519021239 cites W2130735070 @default.
- W2519021239 cites W2131670056 @default.
- W2519021239 cites W2131674211 @default.
- W2519021239 cites W2135657152 @default.
- W2519021239 cites W2137142564 @default.
- W2519021239 cites W2140010849 @default.
- W2519021239 cites W2142105549 @default.
- W2519021239 cites W2143665087 @default.
- W2519021239 cites W2144851947 @default.
- W2519021239 cites W2150844516 @default.
- W2519021239 cites W2154819798 @default.
- W2519021239 cites W2155524619 @default.
- W2519021239 cites W2155851270 @default.
- W2519021239 cites W2159030747 @default.
- W2519021239 cites W2162830031 @default.
- W2519021239 cites W2163294504 @default.
- W2519021239 cites W2164872561 @default.
- W2519021239 cites W2165087712 @default.
- W2519021239 cites W2168953464 @default.
- W2519021239 cites W2281441010 @default.
- W2519021239 cites W2288511411 @default.
- W2519021239 cites W2341389059 @default.
- W2519021239 cites W2395689465 @default.
- W2519021239 cites W2396364698 @default.
- W2519021239 cites W2464314399 @default.
- W2519021239 doi "https://doi.org/10.1038/cgt.2016.39" @default.
- W2519021239 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5083201" @default.
- W2519021239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27632933" @default.
- W2519021239 hasPublicationYear "2016" @default.
- W2519021239 type Work @default.
- W2519021239 sameAs 2519021239 @default.
- W2519021239 citedByCount "6" @default.
- W2519021239 countsByYear W25190212392017 @default.
- W2519021239 countsByYear W25190212392019 @default.
- W2519021239 countsByYear W25190212392020 @default.
- W2519021239 countsByYear W25190212392021 @default.
- W2519021239 crossrefType "journal-article" @default.
- W2519021239 hasAuthorship W2519021239A5027616097 @default.
- W2519021239 hasAuthorship W2519021239A5060329995 @default.
- W2519021239 hasAuthorship W2519021239A5073811035 @default.
- W2519021239 hasAuthorship W2519021239A5075308122 @default.
- W2519021239 hasAuthorship W2519021239A5082762194 @default.
- W2519021239 hasBestOaLocation W25190212391 @default.
- W2519021239 hasConcept C182979987 @default.
- W2519021239 hasConcept C185592680 @default.